Get started
Apellis Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

No trades
Buy APLS
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

APLS chart


Full chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.37 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.74USD
Net income (FY)
‪−528.63 M‬USD
Revenue (FY)
‪396.59 M‬USD
Shares float
‪100.98 M‬
Beta (1Y)
0.21

Employees


Employees (FY)
706
Change (1Y)
−61 −7.95%
Revenue / Employee (1Y)
‪561.74 K‬USD
Net income / Employee (1Y)
‪−748.76 K‬USD

About Apellis Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Cedric Francois
Headquarters
Waltham
Website
apellis.com
Founded
2009
FIGI
BBG007KGRPY4
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

News



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

APLS highest yielding bonds


APLS5052553
Apellis Pharmaceuticals, Inc. 3.5% 15-SEP-2026
Yield to maturity
−1.09%
Maturity date
Sep 15, 2026

Explore more bonds 

Frequently Asked Questions


The current price of APLS is 27.26 USD — it has decreased by −0.90% in the past 24 hours. Watch Apellis Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Apellis Pharmaceuticals, Inc. stocks are traded under the ticker APLS.
APLS stock has risen by 2.39% compared to the previous week, the month change is a −4.32% fall, over the last year Apellis Pharmaceuticals, Inc. has showed a −40.84% decrease.
We've gathered analysts' opinions on Apellis Pharmaceuticals, Inc. future price: according to them, APLS price has a max estimate of 95.00 USD and a min estimate of 25.00 USD. Watch APLS chart and read a more detailed Apellis Pharmaceuticals, Inc. stock forecast: see what analysts think of Apellis Pharmaceuticals, Inc. and suggest that you do with its stocks.
APLS reached its all-time high on Jun 14, 2023 with the price of 94.75 USD, and its all-time low was 11.45 USD and was reached on Oct 24, 2018. View more price dynamics on APLS chart.
See other stocks reaching their highest and lowest prices.
APLS stock is 3.53% volatile and has beta coefficient of 0.21. Track Apellis Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Apellis Pharmaceuticals, Inc. there?
Today Apellis Pharmaceuticals, Inc. has the market capitalization of ‪3.37 B‬, it has increased by 0.47% over the last week.
Yes, you can track Apellis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Apellis Pharmaceuticals, Inc. is going to release the next earnings report on Nov 5, 2024. Keep track of upcoming events with our Earnings Calendar.
APLS earnings for the last quarter are −0.30 USD per share, whereas the estimation was −0.31 USD resulting in a 2.03% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about Apellis Pharmaceuticals, Inc. earnings.
Apellis Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪199.69 M‬ USD, despite the estimated figure of ‪190.89 M‬ USD. In the next quarter, revenue is expected to reach ‪200.00 M‬ USD.
APLS net income for the last quarter is ‪−37.66 M‬ USD, while the quarter before that showed ‪−66.42 M‬ USD of net income which accounts for 43.31% change. Track more Apellis Pharmaceuticals, Inc. financial stats to get the full picture.
No, APLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 1, 2024, the company has 706.00 employees. See our rating of the largest employees — is Apellis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Apellis Pharmaceuticals, Inc. EBITDA is ‪−311.34 M‬ USD, and current EBITDA margin is −129.96%. See more stats in Apellis Pharmaceuticals, Inc. financial statements.
Like other stocks, APLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Apellis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Apellis Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Apellis Pharmaceuticals, Inc. stock shows the strong sell signal. See more of Apellis Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.